Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Harmony Biosciences Holdings Inc shares valued at $16,077 were sold by Dierks Jeffrey on Oct 01 ’24. At $40.19 per share, Dierks Jeffrey sold 400 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, JEFFREY G DIERKS purchased 21,796 shares, netting a total of over 871,840 in proceeds.
Before that, Dierks Jeffrey had sold 35,846 shares from its account. In a trade valued at $1,434,951, the CHIEF COMMERCIAL OFFICER traded Harmony Biosciences Holdings Inc shares for $40.03 each. Upon closing the transaction, the insider’s holdings decreased to 35,846 shares, worth approximately $0.0.
As published in their initiating research note from UBS on September 10, 2024, Harmony Biosciences Holdings Inc [HRMY] has been a Buy and the price target has been revised to $56. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in late June. As of January 02, 2024, BofA Securities has decreased its “Neutral” rating to a “an Underperform” for HRMY. Earlier on September 25, 2023, Goldman downgraded its rating. Their new recommendation was “a Sell” for HRMY stock which previously was a “a Neutral”.
Analyzing HRMY Stock Performance
During the last five days, there has been a drop of approximately -4.61%. Over the course of the year, Harmony Biosciences Holdings Inc shares have jumped approximately 10.12%. Shares of the company reached a 52-week high of $40.60 on 10/01/24 and a 52-week low of $28.14 on 04/25/24. A 50-day SMA is recorded $35.97, while a 200-day SMA reached $32.51. Nevertheless, trading volume fell to 1.02 million shares from 0.44 million shares the previous day.
Support And Resistance Levels for Harmony Biosciences Holdings Inc (HRMY)
According to the 24-hour chart, there is a support level at 34.01, which, if violated, would cause prices to drop to 32.44. In the upper region, resistance lies at 38.38. The next price resistance is at 41.18. RSI (Relative Strength Index) is 41.88 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.31, which suggests the price will decrease in the coming days. Percent R is at 94.02%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
